Next Generation Soft Mist Nasal Sprays for Intranasal Delivery of CNS Therapies
Buchmann N, Verhoeven F, Bilstein A, Muellinger B.
Respiratory Drug Delivery 2025. Volume 1, 2025: 116-123.
Abstract:
Intranasal drug delivery offers a non-invasive route for central nervous system (CNS) therapies via the olfactory pathway. Conventional nasal sprays often fall short in CNS delivery due to high plume velocity and suboptimal droplet size, resulting in predominantly anterior drug deposition. Soft mist nasal sprays (SMNS) overcome these limitations due to their lower plume velocity and narrow droplet size distribution, thereby targeting the posterior nasal regions enhancing olfactory deposition. This review examines the mechanism for effective CNS drug delivery, advantages of SMNS, and preclinical and clinical performance of SMNS platforms. Emerging evidence indicates that SMNS enables optimal drug deposition in posterior-superior nasal regions, supporting its potential for intranasal CNS therapy.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
